The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JT, NKTR, SYF and SONS
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Jianpu Technology Inc. (NYSE: JT) Class Period: Pursuant and/or traceable to the initial public offering on or about November 16, 2017 Lead Plaintiff Deadline: December 24, 2018
The complaint alleges that the Company’s IPO offering materials contained inaccurate statements of material fact and/or omitted material information required to be disclosed in order to make such statements not misleading, including failure to disclose that the China Banking Regulatory Commission and three other Chinese regulators had issued rules in 2016 requiring peer-to-peer lending companies to appoint qualified banking institutions as custodians and disclose their use of deposits. On November 21, 2017, news outlets reported that China’s Financial Stability and Development Committee (“FSDC”) had issued an urgent notice to provincial governments urging them to suspend regulatory approval of new internet micro-loan companies. Following this news, Jianpu’s shares fell over 38% in three days and closed at $4.90 per share on November 24, 2017.
Get additional information about the JT lawsuit: http://www.kleinstocklaw.com/pslra-1/jianpu-technology-inc-loss-submission-form?wire=3
Nektar Therapeutics (NASDAQ: NKTR) Class Period: November 11, 2017 to October 2, 2018 Lead Plaintiff Deadline: December 31, 2018
The lawsuit alleges that throughout the class period, Nektar Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the Company’s lead I-O candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.
Get additional information about the NKTR lawsuit: http://www.kleinstocklaw.com/pslra-1/nektar-therapeutics-loss-submission-form?wire=3
Synchrony Financial (NYSE: SYF) Class Period: October 21, 2016 to November 1, 2018 Lead Plaintiff Deadline: January 2, 2019
The complaint alleges that during the Class Period, Synchrony falsely represented that its consistent and disciplined underwriting practices had led to a higher quality loan portfolio than those of its competitors. In truth, Synchrony relaxed its underwriting standards and increasingly offered private-label credit cards to riskier borrowers to sustain growth. The truth about Synchrony’s credit standards began to be revealed on April 28, 2017, when the Company announced disappointing first quarter 2017 earnings driven by poor loan performance. Following this disclosure, the Company represented that it had tightened credit standards, but falsely characterized those underwriting changes as modest. In fact, the Company had made significant modifications to its underwriting policies, but concealed that these modifications were damaging its relationships with its retail partners, including Walmart.
Get additional information about the SYF lawsuit: http://www.kleinstocklaw.com/pslra-1/synchrony-financial-loss-submission-form?wire=3
Sonus Networks, Inc. (NASDAQ: SONS) (now Ribbon Communications, NASDAQ: RBBN) Class Period: January 8, 2015 to March 24, 2015 Lead Plaintiff Deadline: January 7, 2019
The lawsuit alleges Sonus Networks, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the Company would fall materially short of its $74 million revenue forecast; (2) defendants knew that unrealistic revenue and profitability forecasts remained aspirational and largely unreachable, a fact that senior sales personnel regularly communicated to Defendants; (3) a number of 2015 sales had been “pulled forward” to buoy sales numbers in Q4 2014, at management’s express direction, and (4) the “backlog” of sales expected to be recognized in early 2015 was significantly lower than usual.
Get additional information about the SONS lawsuit: http://www.kleinstocklaw.com/pslra-1/sonus-networks-inc-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.